---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-26-000012"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:44:24.406359+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q4 revenue $281.3M (+39% YoY); 2026 revenue guided $1.25-1.28B

## Summary
- Q4 total revenue $281.3M (+39% YoY); Oncology tests 79k (+38%), Screening tests 38k.
- Full year 2025 revenue $982.0M (+33%); net loss $416.3M ($3.32 EPS) vs $436.4M prior year.
- Adj. EBITDA loss improved to $220.9M (FY) from $257.5M; free cash flow burn $233M vs $275M.
- 2026 guidance: revenue $1.25-1.28B (27-30% growth); Screening revenue $162-174M; volume 210k-225k tests.
- Acquired MetaSight Diagnostics for $59M upfront plus up to $90M contingent consideration.

## SEC filing metadata
- accession: 0001576280-26-000012
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000012/0001576280-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000012/gh-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-26-000012
- JSON: https://secwatch.observer/filing/0001576280-26-000012.json
- Plain text: https://secwatch.observer/filing/0001576280-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.